Before elesclomol was discovered to induce cuproptosis to eliminate tumor cells, it had already been demonstrated to trigger copper-dependent apoptosis or ferroptosis in melanoma, leukemia, or CRC cells by promoting the generation of ROS or facilitating the degradation of ATP7A in the context of anti-tumor therapy (Gao et al., 2021; Kirshner et al., 2008). This evidence concerns the gene ATP7A and melanoma.